Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital reduced their price objective on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Trading Down 5.0 %

EVGN opened at $1.52 on Wednesday. Evogene has a 1-year low of $1.44 and a 1-year high of $10.40. The stock has a market capitalization of $8.16 million, a price-to-earnings ratio of -0.34 and a beta of 1.36. The business has a 50 day moving average of $2.21 and a 200-day moving average of $4.15.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.